Ipsen: closes acquisition of Clementia

(CercleFinance.com) - Ipsen announces closing the acquisition of Clementia Pharmaceuticals following the approval from the Quebec Superior Court and the agreement from Clementia shareholders, who will receive an initial payment of 25 US dollars per share.
 

They will also receive one contingent value right (CVG) per share, ensuring a deferred payment of six dollars per CVG, subject to the FDA's acceptance of the regulatory filing for palovarotene for the treatment of multiple osteochondromas.

Palovarotene, a key molecule in an advanced development phase, is being developed for the treatment of two rare bone disorders, fibrodysplasia progressive ossificans and multiple osteochondromes, as well as other diseases.


Copyright (c) 2019 CercleFinance.com. All rights reserved.